Bateman-House, McBride-Folkers and Caplan Examine “Right to Try” Bill

In a recent post on the IVI-sponsored Health Affairs featured blog series, Alison Bateman-House, Kelly McBride-Folkers and Arthur Caplan discuss the Trickett Wendler Right to Try Act of 2017. The authors outline key obstacles likely to limit the effectiveness of the law and present some alternative measures for achieving access to experimental drugs for patients. Read [...]

2017-07-14T07:18:56-04:00May 3rd, 2017|Viewpoints|

FDA’s Scott Gottlieb and The Goldilocks Theory

In a recent post on the IVI-sponsored Health Affairs featured blog series, Ian Spatz outlines the challenges facing new FDA commissioner Scott Gottlieb. Among the challenges identified are the determination of new criteria for the control of medical information and the encouragement of competition to control drug costs. Read the full article here. About the Health Affairs/IVI Featured [...]

2017-07-14T05:25:13-04:00May 1st, 2017|Viewpoints|

Lakdawalla, Sachs, and Bagley Focus on Medicaid’s Best-Price Rule and Trump Administration Opportunity to Advance Value-Based Pricing

In a recent post on the IVI-sponsored Health Affairs featured blog series, IVI's Executive Director, Darius Lakdawalla, along with Rachel Sachs and Nicholas Bagley, examine how Medicaid's best-price rule complicates the development of value-based pricing and suggest a potential solution that could come out of the new Trump administration CMS policies. Read the full article here. About [...]

2017-07-14T05:25:23-04:00April 27th, 2017|Viewpoints|

A Win-Win Strategy for Improving Access to Hepatitis C Medicines

In a recent post on the IVI-sponsored Health Affairs blog series, Neeraj Sood, Gillian Buckley, and Brian Strom present a novel "win-win" scenario for improving patient access to Hepatitis C medicines. By arranging for pharmaceutical patent holders to license their patents to the federal government, the agreement could potentially provide curative treatment to nearly a half [...]

2017-07-14T07:19:45-04:00April 24th, 2017|Viewpoints|

Balancing the Use of Cost-Effectiveness Analysis in Healthcare Innovations

In a recent post on the IVI-sponsored Health Affairs featured blog series, Peter Neumann and James Baumgardner addresses cost effectiveness analysis as applied across different types of of healthcare interventions, and the disproportionate emphasis placed on pharmaceuticals relative to overall healthcare spending. Neumann and Baumgardner outline some reasons why surgical CEAs are more challenging that drug CEAs, [...]

2017-07-14T07:19:55-04:00April 14th, 2017|Viewpoints|

Unique Challenges of Assessing the Value of Treatments for Rare Diseases

In a recent post on the IVI-sponsored Health Affairs featured blog series, IVI's Executive Director, Darius Lakdawalla, and Anupam Jena recommend that creators of value frameworks recognize the unique issues associated with valuing treatments for rare diseases by adopting societal, as well payer-oriented perspectives. Included in this assessment are the important roles of treatment spillovers, societal preferences about health [...]

2017-07-14T07:20:06-04:00April 12th, 2017|Viewpoints|

Rachel Sachs Summarizes Scott Gottlieb’s FDA Commissioner Confirmation Hearing

In a recent post on the IVI-sponsored Health Affairs featured blog series, Rachel Sachs summarizes Scott Gottlieb's FDA Commissioner confirmation hearing and top-lines four areas of questioning: the drug approval process, the character of the FDA, the opioid epidemic, and soaring drug prices. Also notable for not being mentioned, Rachel is curious how Dr. Gottlieb will address the FDA's relationship with [...]

2017-07-14T07:20:20-04:00April 7th, 2017|Viewpoints|

Patent Buyouts and Licensing Changes as a Strategy for Lowering Brand Drug Prices

In a recent post on the IVI-sponsored Health Affairs featured blog series, Jonathan Silver suggests the key to lowering brand drug prices may be found through patent buyouts and changes to licensing policy. In particular, Silver proposes that non-profit entities be created and funded to purchase and license intellectual property rights for certain branded drugs. Read [...]

2017-07-14T07:20:34-04:00April 5th, 2017|Viewpoints|

Addressing Outcomes-Based Pricing Agreements

In a recent post on the IVI-sponsored Health Affairs featured blog series, Daniel Blumenthal, Mark Linthicum (IVI Director of Scientific Communications), and Sachin Kamal-Bahl (Member, IVI Strategic Advisory Panel) discuss challenges in establishing outcomes-based pricing agreements for pharmaceuticals and potential strategies for overcoming obstacles. Strategies discussed include focusing on legal and regulatory changes, increased information sharing, [...]

2017-07-14T07:20:44-04:00April 3rd, 2017|Viewpoints|

Lessons Learned from Genentech-Priority Health Pilot in Illustrating Outcomes-Based Contracting Challenges

In a recent post on the IVI-sponsored Health Affairs featured blog series, John Fox and Marc Waltrous provide a detailed analysis of the Genentech-Priority Health Pilot program, outlining the background, key considerations, pilot design, and take-aways to illustrate the challenges of a successful outcomes-based contracting agreement. Read the full article here. About the Health Affairs/IVI Featured Blog [...]

2017-07-14T07:20:58-04:00April 3rd, 2017|Viewpoints|
Go to Top